Having an intracranial aneurysm coiled is often described as having a bomb defused. The immediate danger is removed, but the risk has not disappeared. For many patients, the harder question comes afterwards: how should the repair be checked, when conventional follow-up means an invasive angiogram?

A Patient Who Chose a Non-Invasive Follow-Up

A 59-year-old woman with an aneurysm of the C7 segment of the right internal carotid artery underwent coil embolization in November 2024. DSA (digital subtraction angiography) would have meant arterial puncture, pain, radiation exposure and the inconvenience of hospitalization with bed rest, and she remained uneasy about it. On her physician's advice, she chose a 3.0T MR angiography protocol combined with hemodynamic assessment, and completed follow-up at six months and one year.

All three key hemodynamic indicators were favorable. The conclusion was that blood flow at the vessel and at the original aneurysm neck was stable, the recurrence risk was low, and the follow-up interval could be extended appropriately.

Through this protocol she avoided the discomfort of an invasive DSA examination and received precise, comfortable post-treatment management. Her case shows that DSA is not the only route after aneurysm treatment and is a reminder that the hidden risks in the years afterwards should not be overlooked.

Why "Defused" Does Not Mean "Cured"

A cerebral aneurysm is not a tumor. It behaves more like an unpredictable device inside the skull: highly occult, prone to recurrence, and associated with high rates of disability and death if it ruptures.

After stent-assisted treatment, long-term pressure from blood flow can deform and compact the embolic material. An aneurysm can recur at the original site or appear elsewhere in the brain, and the stented segment of the vessel can develop stenosis or occlusion. These problems rarely cause obvious symptoms early on and are almost impossible to recognize by how a patient feels; imaging follow-up is the main way to detect them in time.

According to the Chinese Guidelines for the Diagnosis and Treatment of Unruptured Intracranial Aneurysms (2021), recurrence after endovascular treatment reaches 20.8% — roughly one in every five postoperative patients. A second rupture carries a mortality of 60%–80%, and survivors frequently live with hemiplegia, cognitive impairment or epilepsy.

The two conventional options each bring real limitations:

  • DSA is the clinical gold standard for cerebrovascular diagnosis, but it is invasive: infection risk, pain, anesthesia, radiation, hospitalization with bed rest and higher cost.
  • CTA involves a certain radiation dose and an injected contrast agent, with the associated risk of contrast allergy.

Caught between a hidden risk that needs checking and an examination that is painful and restrictive, many patients end up wanting a check-up but not daring to have one — afraid of suffering, and afraid the result still will not be clear. Must pre-treatment assessment and post-treatment follow-up always go through DSA?

Structure Plus Function: A Non-Invasive MR Protocol

The protocol used at UV Clinic for aneurysm pre-treatment assessment and post-treatment follow-up was jointly developed with the neurosurgery team of Prof. Yang Xinjian at Beijing Tiantan Hospital, Capital Medical University, and put into clinical application by QuanJing Medical Imaging.

It brings three clinical advantages:

  • Painless, non-invasive, radiation-free, walk-in walk-out — no puncture, anesthesia, hospitalization or contrast agent, so contrast allergy is avoided and daily life is uninterrupted.
  • High accuracy benchmarked against DSA — multiple domestic and international studies have shown strong agreement between MRA and DSA findings; the protocol can simulate the forces blood flow exerts on the vessel wall and clearly identify a residual aneurysm neck.
  • AI-assisted automatic analysis — morphological parameters are measured automatically, nine key hemodynamic indicators are interpreted, and new imaging can be compared with earlier studies to visualize how a lesion changes.

The clinical logic is straightforward: begin with non-invasive assessment; if the result is stable, an invasive puncture may be avoided; if a suspicious abnormality is detected, proceed to deeper investigation. The protocol was developed by a leading academic team, is supported by guideline literature and has been validated across a large number of clinical cases. UV Clinic's specialist team, extensive diagnostic experience and imported imaging systems provide the practical foundation for delivering it.

Putting the Choice in Context

For families after aneurysm treatment, recovery is only part of the concern; deciding how to handle follow-up can be just as difficult. There is the worry about puncture, and the worry about radiation. As clinical protocols continue to evolve, 3.0T MR combined with hemodynamic assessment offers some families one more option. Following the treating physician's advice on follow-up remains an important part of protecting cerebrovascular health.

This article is general health information based on a case-sharing example and is not medical advice. Any post-processing data analysis report is based on the images from that examination and the information provided, is for clinical reference only, and the final imaging diagnostic report prevails. Please follow your treating physician's instructions for any examination or treatment decision, and consult a qualified clinician before changing medication or follow-up plans.

References

  • [1] Chinese Guidelines for the Diagnosis and Treatment of Unruptured Intracranial Aneurysms 2021. Chinese Journal of Cerebrovascular Diseases, 2021, 18(9): 634-664.
  • [2] Chinese Expert Consensus on Endovascular Treatment of Intracranial Aneurysms (2013). National Medical Journal of China, 2013, 93(39): 3097-3103.
  • [3] Matsushige T, Shimonaga K, Mizobuchi Y, et al. Usefulness of Silent Magnetic Resonance Angiography in the Follow-Up of Endovascular-Treated Intracranial Aneurysm. Clin Neuroradiol, 2022, 32(3): 789-798; Kono K, et al. J Neuroradiol, 2021, 48(4): 245-252.